Health-related quality of life and cognitive functioning in adult patients with supratentorial WHO grade II glioma: status prior to therapy

The present prospective study intends to evaluate health-related quality of life (HRQL) and cognitive functioning in adult patients with supratentorial World Health Organization (WHO) grade II glioma (LGG) prior to observation/therapy and to determine possible influences of tumor-related factors on these measures. Adult patients with biopsy-proven supratentorial LGG were considered eligible (study period 18 months). Besides detailed documentation of patient clinical status we evaluated HRQL using the Short Form-36 (SF-36) Health Survey and applied the Beck Depression Inventory. Furthermore, attention and verbal memory functions were tested. Data from matched healthy control populations served as reference, and T-values were compared using Mann–Whitney U tests. For correlation of scores the Pearson test was utilized. Thirty-three patients with median Karnofsky Performance Status (KPS) of 80 were evaluated. Selective and divided attention showed significant impairment (P < 0.005), while verbal memory functions were unaffected. HRQL evaluated by SF-36 Health Survey was significantly reduced predominantly in the psychological domains (P < 0.025 to P < 0.0005). Nine patients displayed mild to moderate depression. Duration of symptoms >20 weeks and presence of seizures negatively affected aspects of HRQL, while cognitive functions were not influenced. KPS <80 correlated significant only with reduced physical functioning (P < 0.002) and role functioning (P < 0.01) on the SF-36 Health Survey. While displaying good clinical status, patients with LGG showed significant impairment in aspects of attention and affections of HRQL already at time of diagnosis. These results suggest that these impairments originate from the tumor and/or potentially from confrontation with the diagnosis itself.

[1]  Martin Klein,et al.  Cognitive deficits in adult patients with brain tumours , 2004, The Lancet Neurology.

[2]  Desmond Curran,et al.  Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised Phase III trial on dose response (EORTC trial 22844) , 1998 .

[3]  R. Mccomb,et al.  Pathology and Genetics of Tumours of the Nervous System , 1998 .

[4]  D. Correa,et al.  Cognitive functions in low-grade gliomas: disease and treatment effects , 2006, Journal of Neuro-Oncology.

[5]  A. Karim,et al.  Assessment of quality of life in patients treated for low-grade glioma: a preliminary report. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[6]  D. Osoba,et al.  An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. , 2010, European journal of cancer.

[7]  Douglas C. Miller,et al.  Treatment and survival of low-grade astrocytoma in adults--1977-1988. , 1992, Neurosurgery.

[8]  A. Karim,et al.  Cognitive functions and quality of life in patients with low‐grade gliomas: The impact of radiotherapy , 1994, Annals of neurology.

[9]  M. Bitterman THE EVOLUTION OF INTELLIGENCE. , 1965, Scientific American.

[10]  Jan J. Heimans,et al.  Impact of brain tumour treatment on quality of life , 2002, Journal of Neurology.

[11]  U. Gschwandtner,et al.  Testbatterie zur Aufmerksamkeitsprüfung (TAP) Version 1.7 , 2003 .

[12]  M. Bullinger German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. , 1995, Social science & medicine.

[13]  L. Deangelis,et al.  Long-term outcome of low-grade oligodendroglioma and mixed glioma , 2000, Neurology.

[14]  J. Piepmeier Current concepts in the evaluation and management of WHO grade II gliomas , 2009, Journal of Neuro-Oncology.

[15]  L. Douw,et al.  Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up , 2009, The Lancet Neurology.

[16]  M. Taphoorn,et al.  Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas , 2001, Neurology.

[17]  N. Aaronson,et al.  How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Twijnstra,et al.  Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Colin M. MacLeod,et al.  Evaluation of chemotherapeutic agents , 1949 .

[20]  D. Bjorklund,et al.  Social cognition, inhibition, and theory of mind: The evolution of human intelligence , 2002 .

[21]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[22]  Martin Klein,et al.  Epilepsy in low‐grade gliomas: The impact on cognitive function and quality of life , 2003, Annals of neurology.

[23]  M. Faist,et al.  Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas , 1997, Cancer.

[24]  J. Jolles,et al.  Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study , 2002, The Lancet.

[25]  Lauren E. Abrey,et al.  Longitudinal cognitive follow-up in low grade gliomas , 2008, Journal of Neuro-Oncology.

[26]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[27]  D. Delis,et al.  The California verbal learning test , 2016 .

[28]  D. Karnofsky The clinical evaluation of chemotherapeutic agents in cancer , 1949 .